Treatment for Subjects With Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2004-02-01
Target enrollment:
Participant gender:
Summary
This multicenter, open-label, randomized, parallel study was designed to evaluate whether a
single fixed-dose subcutaneous (SC) administration of pegfilgrastim or daily administration
of Filgrastim for absolute neutrophil count (ANC) support would assist in allowing the
planned dose-on-time (PDOT) of cyclophosphamide, doxorubicin, vincristine, prednisolone
(CHOP) chemotherapy with Rituximab every 14 days in subjects with aggressive B-cell
Non-Hodgkin's Lymphoma by reducing the duration of neutropenia and incidence of febrile
neutropenia.